Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
An economic evaluation can provide insights into the cost-effectiveness of different kidney replacement therapy modalities to inform decisions on how to best allocate limited resources. This evidence-based Guideline is aimed at equipping policymakers and medical personnel with insight into the principles of economic evaluation within the context of policies for kidney-failure services, and increasing their confidence in requesting and using economic evidence derived from such evaluations.
The management of X-linked hypophosphataemia has evolved owing to the availability of burosumab. In this Evidence-Based Guideline, the authors provide updated clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia with the aim of improving patient outcomes and quality of life.
